gilead-sciences

Gilead’s CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma

pharmafile | October 8, 2019 | News story | Manufacturing and Production, Sales and Marketing |  CAR T, CAR-T, NHS, Scotland, Scottish Medicines Consortium, pharma 

News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor T cell (CAR-T) therapy Yescarta (axicabtagene ciloleucel) on the NHS in Scotland.

Following the decision, patients will be able to receive the therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), in adult patients who have tried two or more lines of systemic therapy.

The ruling marks the second NHS approval of a CAR-T therapy in Scotland, following Novartis’ Kymriah (tisagenlecleucel) earlier this year for the treatment of relapsed/refractory DLBCL in adults and acute lymphoblastic leukaemia.

Advertisement

“This is further good news for people affected by lymphoma as it means there is wider access to CAR T cell therapy in Scotland. It is important for people affected by DLBCL and particularly significant for people affected by primary mediastinal B-cell lymphoma, for whom CAR T cell therapy would not otherwise be available in Scotland,” remarked Stephen Scowcroft, Director of Operations and External Affairs at Lymphoma Action.

General Manager, Gilead UK & Ireland’s General Manager Hilary Hutton-Squire also remarked: “This is an important day for patients in Scotland with certain aggressive forms of blood cancer. Yescarta is an individualised cell therapy that provides a valuable treatment option for patients who have exhausted other therapies, meaning they may have just months left to live, potentially changing their outcomes.” 

Matt Fellows

Related Content

Five Facts about NHS and primary care

1 Primary care is the front door to the NHS, but it extends well beyond …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Major funding opportunity opens for early cancer diagnostics

Up to £25.4m in funding is available for collaborative projects developing technologies to improve the …

The Gateway to Local Adoption Series

Latest content